Faron Pharmaceuticals: Promising BEXMAB Interim Update - Redeye

Redeye leaves a note following Faron’s additional study update from the phase I/II BEXMAB study with lead candidate Bexmarilimab. We are encouraged by the ongoing positive progress and favorable response to treatment in hematological malignancies.

Länk till analysen i sin helhet: https://www.redeye.se/research/894153/faron-pharmaceuticals-promising-bexmab-interim-update?utm_source=finwire&utm_medium=RSS